— Bio-Path Holdings, Inc. (NASDAQ: BPTH) reported a net loss of $2.2 million or $0.78 share for the third quarter of 2019, vs. $0.74 per share loss expected.
— Research and development expenses decreased to $1.4 million from $2.3 million last year
— General and administrative expenses were $0.9 million during the three-month period, up 29% from last year
— Recorded cash of $15.4 million as of September 30, 2019, compared to $1.0 million at December 31, 2018
— Net cash used in operating activities was $6.1 million during the nine-month period ended September, compared to $4.8 million last year
— Recently, appointed Martina Molsbergen, chief executive officer of C14 Consulting, to the board of directors of Bio-Path
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
